,,ii #aagth ,,congress #b;d ,session ,s4 #dbae ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,may #ab1 #bjbb,mr4 ,rubio 7for himself and ,mr4 ,bennet7 introduced the following bill2 which was read twice and referred to the ,committee on ,health1 ,education1 ,labor1 and ,pensions ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act to establish additional authorities of the ,food and ,drug ,administration regarding the conduct of pediatric investigations of molecularly targeted drugs to treat cancer1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,give ,kids a ,chance ,act of #bjbb4 #b4 ,research into pediatric uses of drugs2 additional authorities of ,food and ,drug ,administration regarding molecularly targeted cancer drugs 7a7 ,in general 7#a7 ,additional active ingredient for application drug2 limitation regarding novel-combination application drug ,section #eje;,b7a77#c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee;c7a77#c77 is amended-- 7,a7 by redesignating subparagraphs 7,b7 and 7,c7 as subparagraphs 7,c7 and 7,d71 respectively2 and 7,b7 by striking subparagraph 7,a7 and inserting the following3 7,a7 ,in general ,for purposes of paragraph 7#a77;,b71 the investigation described in this paragraph is 7as determined by the ,secretary7 a molecularly targeted pediatric cancer investigation of-- 7i7 the drug or biological product for which the application referred to in such paragraph is submitted2 or 7ii7 such drug or biological product in combination with-- 7,i7 an active ingredient of a drug for which an approved application under section #eje7;j7 is in effect or an active ingredient of a biological product for which an approved application under section #cea7k7 of the ,public ,health ,service ,act is in effect1 which drug or biological product is determined by the ,secretary to be the standard of care for treating a pediatric cancer2 7,,ii7 an active ingredient of a drug for which an approved application under section #eje7;b7 is in effect to treat an adult cancer1 or an active ingredient of a biological product for which an approved application under section #cea7;a7 of the ,public ,health ,service ,act is in effect to treat an adult cancer1 which approved application is held by the same person submitting the application2 or 7,,iii7 an active ingredient of a drug or biological product for which there is in effect an exemption for investigational use under section #eje7;i71 which drug or biological product is under such exemption being studied jointly by the person submitting the application referred to in paragraph 7#a77;,b7 and by another person pursuant to an agreement between such persons4 7,b7 ,additional requirements 7i7 ,design of investigation ,a molecularly targeted pediatric cancer investigation referred to in subparagraph 7,a7 shall be designed to yield clinically meaningful pediatric study data1 gathered using appropriate formulations for each age group for which the study is required1 regarding dosing1 safety1 and preliminary efficacy to inform potential pediatric labeling4 7ii7 ,limitation ,studies described in subparagraph 7,a77ii7 may be required only if the drug or biological product for which the application referred to in paragraph 7#a77;,b7 contains either-- 7,i7 a single new active ingredient2 or 7,,ii7 more than one active ingredient1 if an application for the combination of active ingredients has not previously been approved but each active ingredient has been previously approved to treat an adult cancer4 7iii7 ,preclinical data ,the ,secretary may require that reports on an investigation required pursuant to paragraph 7#a77;,b7 include the results of all preclinical studies on which the decision to conduct such investigation was based4 7iv7 ,rule of construction regarding inactive ingredients ,with respect to a combination of active ingredients referred to in subparagraph 7,a77ii71 such subparagraph shall not be construed as addressing the use of inactive ingredients with such combination4 4 7#b7 ,conforming amendments ,section #eje;,b7a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee;c7a77 is amended-- 7,a7 in paragraph 7#c77;,c71 as redesignated by paragraph 7#a77;,a7 of this subsection1 by striking investigations described in this paragraph and inserting investigations referred to in subparagraph 7,a77i72 and 7,b7 in paragraph 7#c77;,d71 as redesignated by paragraph 7#a77;,a7 of this subsection1 by striking the assessments under paragraph 7#b77;,b7 and inserting the assessments required under paragraph 7#a77;,a74 7b7 ,authority regarding preclinical studies ,section #eje;,b7a77#a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee;c7a77#a77 is amended by adding at the end the following3 7,c7 ,preclinical studies generally 7i7 ,in general ,with respect to a submission for an exemption for investigational use under section #eje7;i7 for a drug or biological product that is intended for the treatment of an adult cancer1 the ,secretary may require1 as a condition of permitting the exemption to go into effect1 that the sponsor involved enter into an agreement with the ,secretary to conduct not more than #b preclinical studies of the drug or biological product in order to assist in determining the relevance of its molecular target to the growth or progression of a pediatric cancer4 7ii7 ,timeframe for preclinical studies ,with respect to the drug or biological product involved1 an agreement under clause 7i7 for a preclinical study shall specify the date by which an initial plan for the study will be submitted to the ,secretary except that the ,secretary may not require the submission of such plan any earlier than #ij days after the exemption referred to in clause 7i7 goes into effect4 ,the results of the preclinical study shall be submitted to the ,secretary in accordance with a timeframe to which the ,secretary and the sponsor involved have agreed4 ,such timeframe shall provide for deferrals equivalent to deferrals under paragraphs 7#d7 and 7#e74 7iii7 ,use of preclinical study results ,the ,secretary may not use the results of the preclinical studies under clause 7i7 to require additional clinical studies under subparagraph 7,b7 other than the pediatric cancer studies specified in the agreement under clause 7i74 4 7c7 ,applicability ,the amendments made by this section apply with respect to any submission under section #eje7;i7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7;i771 any application under section #eje of such ,act 7#ba ,u4,s4,c4 #cee71 and any application under section #cea7;a7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb71 that is submitted on or after the date that is #b years after the date of enactment of this ,act4 7d7 ,report to ,congress ,not later than #a year after the date of enactment of this ,act1 the ,secretary of ,health and ,human ,services shall submit a report to ,congress on the ,secretary's efforts1 in coordination with industry1 to ensure implementation of the amendments made by subsections 7a7 and 7b7 by the date that is #b years after the date of enactment of this ,act4